Roots Analysis

MAY 2, 2022

In the past few years, plants have been gaining a rapid traction, involving genetic modification and expression of new genes in plant host cells. Currently, a large number of plant-based proteins are being evaluated in clinical phases of development, including vaccine candidates against COVID 19 and multiple rare therapeutic disorders.

Protein 52

Protein Development Manufacturing Marketing 52

pharmaphorum

SEPTEMBER 14, 2020

Merck & Co has signed a multi-billion cancer drug development deal, which will see it investing $1 billion in partner Seattle Genetics. US-based Merck, known as MSD outside North America, will globally develop and market Seattle’s investigational antibody-drug conjugate (ladiratuzumab vedotin). billion equity investment in 5.0

Genetics 52

Genetics Development Drugs Sales 52

The Pharma Data

JULY 8, 2021

Today, access to the world’s largest browsable resource linking rare protein-coding genetic variants to human health and disease was launched through a genetic exome sequence analysis collaboration between AbbVie (NYSE: ABBV), Biogen Inc. Nasdaq: BIIB) and Pfizer (NYSE: PFE). About the UK Biobank.

Genetics 52

Genetics Biobanking Protein Containment 52

The Pharma Data

JULY 15, 2021

The access to the world’s largest browsable resource linking rare protein-coding genetic variants to human health and disease was launched through a genetic exome sequence analysis collaboration between AbbVie (NYSE: ABBV), Biogen Inc. Nasdaq: BIIB) and Pfizer (NYSE: PFE).

Biobanking 52

Biobanking Genetics Protein Medicine 52

pharmaphorum

APRIL 23, 2021

billion in milestone payments in the deal, which will focus on using small-molecule compounds to “fine tune” the effects of genetic medicines in the body. The approach relies on the use of drug responsive domains (DRDs) on the gene-editing medicine, which can be used to either increase or decrease protein expression.

Gene Editing 52

Gene Editing Genetics Drugs Gene 52

Pharmaceutical Technology

JULY 6, 2022

The European Commission (EC) has granted approval for the expanded conditional marketing authorization (CMA) of Novavax’s Covid-19 vaccine, Nuvaxovid (NVX-CoV2373), in the European Union (EU) for adolescents of the age 12 to 17 years. A protein-based vaccine, NVX-CoV2373 is made from the genetic sequence of the SARS-CoV-2 virus’ first strain.

Vaccination 264

Vaccination Vaccine Protein Clinical Trials 264

Pharmaceutical Technology

JULY 12, 2022

A protein-based vaccine, NVX-CoV2373 is created from the genetic sequence of the SARS-CoV-2 virus’ initial strain. It is formulated with the company’s saponin-based Matrix-M and also comprises a purified protein antigen.

Vaccination 162

Vaccination Vaccine Protein Pharmacy 162

Outsourcing Pharma

JUNE 7, 2023

Duchenne Muscular Dystrophy (DMD) is a genetic disorder that primarily affects males, caused by a mutation in the gene that encodes for a protein called dystrophin. This protein is crucial for the normal functioning of muscles, and its absence leads to progressive muscle weakness and wasting.

Protein 80

Protein Genetics Gene Research 80

World of DTC Marketing

DECEMBER 29, 2020

These vaccines were developed using different “platform technologies” that involve slotting genetic material from the virus into a tried and tested delivery package. It’s estimated that the COVID 19 vaccine market could be worth almost $100 billion. That’s a hell of an incentive.

Vaccination 307

Vaccination Vaccine Development Clinical Trials 307

Pharmaceutical Technology

JUNE 15, 2023

The market responded warmly to the reanalysis. Shares in Eloxx were up 19% at market open compared to previous day’s (14 June) close. Eloxx is conducting a Phase II trial (NCT05448755) investigating ELX-02 in the treatment of Alport syndrome – a genetic disorder characterised by kidney disease.

Trials 246

Trials Genetics Protein Marketing 246

Drug Discovery World

JUNE 1, 2023

A Nature publication confirmed that there are currently 12 FDA-approved ADCs on the market, and nine of these secured FDA approval in the past six years 2. DDW’s Megan Thomas explores three trends in the market. Varying sources suggest that China has been one to watch over recent years and continues to be going forward.

Antibody 98

Antibody Marketing Drugs Licensing 98

Pharmaceutical Technology

FEBRUARY 14, 2023

It will also support smaller dose vials development, selection of strain as per the US Food and Drug Administration (FDA) recommendations, and transition to the commercial market. The company stated that the deal would maintain the access of the US public to its vaccine.

Vaccination 162

Vaccination Vaccine Protein Engineer 162

Pharmaceutical Technology

JUNE 13, 2023

Ziftomenib targets the menin-KMT2a protein-protein interaction that may occur in patients with KMT2ar or NPM1m genetic alterations. The aberrant protein complex is essential for regulating leukaemia-promoting gene expression. Thus, targeting menin may be an effective strategy for patients with high unmet needs.

Gene Expression 130

Gene Expression Protein Sales Genetics 130

Drug Discovery World

MAY 21, 2024

PrimeCap T7 RNA Polymerase is a mutant T7 RNA polymerase that has been genetically engineered to maintain high-performance RNA synthesis activity while reducing dsRNA production to less than 10%. Takara Bio has launched PrimeCap T7 RNA Polymerase (low dsRNA), a mutant T7 RNA polymerase suitable for mRNA therapeutic research and development.

Production 59

Production RNA In-Vitro Genetic Engineering 59

Roots Analysis

MARCH 16, 2023

It is important in the process of protein synthesis because mRNA is responsible for transferring genetic information from DNA to ribosomes, which then decodes the genetic information into a protein. What are the key trends that are shaping up the mRNA therapeutics and vaccines market?

Vaccination 52

Vaccination Vaccine DNA Protein 52

Pharmaceutical Technology

JANUARY 19, 2023

Nuvaxovid is a protein-based vaccine created from the genetic sequence of the initial SARS-CoV-2 virus strain. Novavax president and CEO Stanley Erck said: “We are pleased to collaborate with SK bioscience to offer our protein-based vaccine, Nuvaxovid, for use as a booster in adults regardless of previous vaccine history.

Vaccination 147

Vaccination Vaccine Immune Response Protein 147

Drug Discovery World

JUNE 23, 2023

Sarepta Therapeutics’ Elevidys has become the first gene therapy for Duchenne muscular dystrophy (DMD) to gain marketing authorisation in the US. The FDA’s accelerated approval is based on an increase in Elevidys micro-dystrophin protein expression in skeletal muscle.

Gene Therapy 97

Gene Therapy FDA Approval Gene Protein 97

Pharmaceutical Technology

SEPTEMBER 22, 2022

AVR-RD-04 works by genetically modify a patient's hematopoietic stem cells (HSCs) to express the gene that encodes the cystinosin protein. Cystinosis patients have a high deficiency of this protein. A rare and fatal ailment, cystinosis is characterised by cystine buildup in cellular organelles called lysosomes.

Gene Therapy 147

Gene Therapy Gene Protein Clinical Trials 147

Drug Discovery World

APRIL 17, 2024

JMB: Regulatory RNAs (or regRNAS) are molecules that directly control the expression of nearby protein-coding genes. JMB: There’s no doubt that it’s been a tough environment to raise funds, and the market has only worsened in 2023. JMB: Hundreds of genetic diseases involve a missing or deficient protein and/or enzyme.

Gene Expression 59

Gene Expression Gene Genetic Disease RNA 59

Pharmaceutical Technology

FEBRUARY 13, 2023

Gene therapies are an attractive way of targeting the underlying genetic mutations, but traditional approaches cannot be used while targeting mutations for Dravet Syndrome, forcing researchers to develop new ways. Meanwhile, others are researching the link between gene variation and different responses to treatments.

Research 264

Research Gene Gene Therapy Genome 264

Pharmaceutical Technology

JUNE 29, 2022

Specialty enzymes are proteins that can act as very specific biocatalysts to accelerate reactions and produce the desired target molecule in pharmaceuticals,” explains Kristoffer Laursen, Head of R&D at Novo Nordisk Pharmatech. “In In the evolving biotechnology industry, enzymes are important process aids.

Drugs 295

Drugs Gene Therapy Manufacturing Production 295

Drug Discovery World

APRIL 30, 2024

Messenger RNA (mRNA) has come into focus within the drug discovery and development as an exciting tool to deliver genetic information. For instance, consider how at the end of 2018, the mRNA therapies market was valued at $3.43 Reece Armstrong explores the potential and future opportunities for mRNA-based therapies.

RNA 52

RNA Protein Vaccination Vaccine 52

Drug Discovery World

FEBRUARY 21, 2024

This is done without any genetic modification. The end result is the production of billions of highly enhanced powerful NK cells that can be given via intravenous infusion and cross the blood-brain barrier to help remove proteins like Amyloid, Tau, and alpha-synuclein and to reduce neuroinflammation.

Protein 122

Protein Trials Genetics Antibody 122

XTalks

OCTOBER 20, 2023

Hereditary ATTR (ATTRv) amyloidosis occurs due to mutations in the TTR gene, which causes the liver to produce structurally abnormal transthyretin (TTR) protein with a tendency to misfold. Using CRISPR/Cas9, it knocks out the faulty TTR gene that leads to the production of abnormal TTR protein.

In-Vivo 52

In-Vivo Gene Editing Trials Gene 52

Pharmaceutical Technology

MAY 25, 2023

DMD is a rare genetic disorder caused by changes to the dystrophin protein, leading to progressive muscular degeneration. The FDA has told Sarepta that in this additional timeframe, it will complete final label negotiations and work out post-marketing commitments.

Gene Therapy 130

Gene Therapy Gene Clinical Trials Clinical Trials 130

Drug Discovery World

JULY 6, 2023

The drug candidate, a monoclonal antibody (mAb) targeting the protein Semaphorin-3A (Sema3A), is being developed as a potential first-to-market treatment for Alport syndrome, a rare genetic kidney disease. Semaphorin-3A is an extracellular guidance protein and a well-known regulator of the actin cytoskeleton.

Antibody 52

Antibody Trials Genetics Protein 52

Drug Discovery World

FEBRUARY 6, 2024

Sanofi has stated that it intends to become the first pharma company “powered by AI at scale”, and as part of this ambition, agreed a collaboration with BioMap to co-develop advanced AI models and protein Large Language Models that that it hopes will enable biologics design and multiparametric optimisation 2.

Marketing 69

Marketing Medicine Genome Genomics 69

XTalks

MARCH 7, 2024

Industry professionals will explore the market, innovative formulations and nutritional solutions tailored to empower women toward optimal health and well-being. The test accurately identified a range of genetic abnormalities, including trisomies and microdeletions.

Hormones 115

Hormones Genetics Genome Genomics 115

Advarra

JANUARY 11, 2024

Adoptive T Cell therapies, therapeutic antibodies, and immunomodulatory proteins represent just some of the potentially beneficial treatment strategies for successful mRNA cancer trials. The mRNA constructs used in COVID-19 vaccines, for example, direct cells to produce a version of the “spike” protein studding the surface of SARS-CoV-2.

Vaccination 52

Vaccination Vaccine Protein Antibody 52

pharmaphorum

NOVEMBER 7, 2022

This month, we highlight new appointments from Lumeris, Lineage Cell Therapeutics, 1910 Genetics, and ADC Therapeutics. . As we continue to enter new markets, grow within our existing markets and reach a broader population, we continue to invest in our operations, talent and technology capabilities to support that growth.”

Life Science 98

Life Science Genetics Business Development Marketing 98

Drug Discovery World

AUGUST 28, 2023

It is the method for removing unwanted debris, e.g., old proteins, and breaking them down so their constituent parts can be used again. In most forms of neurodegeneration, toxic protein aggregates build up in the brain and the body’s only method of removing these is via autophagy. DS: What role does genetics play in autophagy?

Genetics 52

Genetics Protein Genetic Disease Clinical Trials 52

Worldwide Clinical Trials

MAY 30, 2024

Since marketing authorization for the first breakthrough treatment in 1994, the steady increase in clinical trials reflects the community’s commitment to finding effective ALS treatments despite the numerous hurdles associated with clinical trial design, from proof-of-concept to pivotal trials. Director, Therapeutic Area Medical Lead.

Gene 162

Gene Clinical Trials Clinical Trials Gene Therapy 162

Roots Analysis

FEBRUARY 13, 2023

Messenger ribonucleic acid (mRNA) is a single-stranded molecule, which carries coding sequence and plays a prominent role in protein synthesis. It transfers genetic information form to DNA to ribosomes, a specialized structure, or organelle, which decodes genetic information into a protein.

Manufacturing 52

Manufacturing Drug Delivery Systems Genetic Engineering RNA 52

Pharmaceutical Technology

JULY 7, 2022

Genetic mutations, both germline and acquired, are behind a large proportion of the most debilitating and sometimes life-threatening human diseases. But scientists have struggled to find effective treatments for many of these diseases since the dawn of modern medicine. A new frontier in cancer research.

Gene Therapy 245

Gene Therapy Gene Medicine Genetics 245

Pharmaceutical Technology

AUGUST 17, 2022

Merck (MSD outside North America) has entered a partnership agreement with Orna Therapeutics for discovering, developing and marketing various programmes based on next-generation RNA technology. These programmes will include therapies and vaccines in infectious disease and oncology areas.

RNA 147

RNA Vaccination Vaccine In-Vivo 147

Delveinsight

JANUARY 18, 2021

Angelman syndrome (AS) is a complex genetic rare disorder that affects the nervous system. The present Angelman syndrome treatment market revolves around the management of symptoms rather than curing the condition. . However, the journey to secure the FDA nod in the Angelman syndrome market landscape does not seem to be all flowery.

Marketing 52

Marketing Gene Drugs Protein 52

Delveinsight

SEPTEMBER 3, 2021

Further, there exist no curative therapies in the Charcot-Marie-Tooth disease market. The present CMT disease therapeutics market is purely based on supportive and symptomatic management that includes occupational therapies, physiotherapy, ankle-foot orthoses (AFO), and shoe inserts. The condition has no cure at hand.

Pharma Companies 52

Pharma Companies Marketing Clinical Trials Clinical Trials 52